Amending Directive to the Use

The EU Directive 95/63/EC, the Amending Directive to the Use of Work Equipment Directive (AUWED), lays down wide-ranging requirements for the provision, management and use of mobile, self-propelled and remote-controlled work equipment, inspection of work equipment, provision and use of lifting equipment, and the management of lifting operations. 

AUWED Amended directive to the Use of Work Equipment Directive CDM Construction (Design and Management) Regulations 1994... 

These Regulations (PUWER 98) replace an earlier 1992 set of the same name, which implemented the first EC directive on work equipment — the Use of Work Equipment Directive (known as UWED). The European Council of Ministers agreed a further directive — the Amending Directive to the Use of Work Equipment (AUWED) — in 1995, and PUWER 98 (S11998 No 2306) implements that Directive in the UK. 

In November, 1985, the Commission submitted to the Council a draft regulation that would ban natural hormones, except for therapeutic purposes, and banned synthetic hormones altogether. In December, 1985, the Commission s proposal to amend Directive 81/602 to prohibit use of anabolics was adopted by the Council and became Council directive EC 85/649. The directive banned the use of natural hormones except for therapeutic purposes and absolutely banned the use of synthetic hormones. The directive also imposed a trade clause that required Member States to prohibit importation from third countries of live animals and of meat from animals to which have been administered in any way whatever substances with a thyreostatic, estrogenic, androgenic, or gestagenic action. Member States were required to bring this directive into force no later than January 1, 1988. 

These measures, heavily altered, reached final adoption in December 2002, as a formal Amendment to the Use Ban Directive of 1976 that relates to restrictions imposed on the marketing and use of certain substances deemed dangerous after suitable scientific investigation. 

For example, the Limitations Directive prohibited the use of chloro-l-eth-ylene for one application, as an aerosol propellant. In some cases, notably with respect to PCBs, the Limitations Directive imposed an outright ban. Restrictions were based on the potential to pose a risk to human health, particularly from carcinogenicity or in some cases a potential risk to the environment. Under the initial Directive and multiple amendments, authorities restricted 42 substances or groups of substances, which included a total of approximately 900 compounds. ... 

The federal Superfund Amendments and Reauthorization Act (SARA Title III) and the Emergency Planning and Community Right-To-Know Act (EPCRA) have several components that are of direct relevance to the use of chemicals. First, they address community emergency planning in event of a hazardous chemical release. There is also provision for emergency notification of state officials of a spill or release of any chemical above a specified amount (referred to as a reportable... 

European Commission (2004) Directive 2004/42/CE of the European Parliament and of the Council of 21 April 2004 on the limitation of emissions of volatile organic compounds due to the use of organic solvents in certain paints and varnishes and vehicle refinishing products and amending Directive 1999/13/EC. Off. /., L143, 87-96. 

EEC Directive amending Directive 76/769/EEC relating to restnctions on the marketing and use of... 

Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC Amended by Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use... 

With respect to development pharmaceutics data, the requirements stated in Directive 75/318/EEC (as amended) are included in the Annex to that document at Part 2 A 4 (page 20 of the Rules Governing Medicinal Products in the European Union, Volume 1, Pharmaceutical Legislation Medicinal Products for Human Use). With respect to the general requirement for pharmaceutical products this states 4.1 An explanation should be provided with regard to the choice of composition, constituents and container and the intended function of the excipients in the finished product. This explanation shall be supported by scientific data on development pharmaceutics. The overage, with justification thereof, should be stated. This, then, is the legal requirement. Needless to say, there is a... 

---